Home / Community / News / News


11/16/2015 - 2:44pm

The Myotonic Dystrophy Foundation partnered with Silicon Valley Research Group to develop a survey to better understand how people with DM weigh the benefits of new treatments again the risks. 

11/04/2015 - 11:38am

MDF is pleased to welcome Tom Cooper, MD, to our Scientific Advisory Committee (SAC). Dr. Cooper, who joined the SAC in summer 2015, is a renowned myotonic dystrophy (DM) investigator whose laboratory has made major contributions to understanding the molecular pathogenesis of the disease and pointing the way toward rational therapeutic development.

10/20/2015 - 1:51pm

At MDF's annual conference in September we heard from four of the newest MDF-funded Fellows, and from three pharmaceutical companies involved in early stage drug development for myotonic dystrophy.

10/13/2015 - 9:35am

Researchers from Ionis Pharmaceuticals collaborated with university teams from across North America to test out what could be the next generation of antisense drugs targeting myotonic dystrophy type 1 (DM1). As our community knows, the potential therapy currently in a phase I/II clinical trial, IONIS-DMPKRx, is also an antisense drug.

10/10/2015 - 6:44pm

The Clinical Trials Transformation Initiative (CTTI), a public-private partnership between Duke University and the FDA focused on increasing the efficiency of clinical trials, has released a detailed series of recommended best practices for interactions between patient groups and clinical trial sponsors.


University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.